Free Trial
ASX:NOX

Noxopharm (NOX) Stock Price, News & Analysis

Noxopharm logo

About Noxopharm Stock (ASX:NOX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.23 million shs
Average Volume
N/A
Market Capitalization
$26.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions; and Sofra platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases. The company was incorporated in 2015 and is based in Glenhaven, Australia.

Receive NOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Noxopharm and its competitors with MarketBeat's FREE daily newsletter.

NOX Stock News Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
Noxopharm Issues New Unquoted Equity Securities
See More Headlines

NOX Stock Analysis - Frequently Asked Questions

Noxopharm Limited (ASX:NOX) announced its earnings results on Thursday, February, 21st. The company reported ($0.04) earnings per share (EPS) for the quarter. Noxopharm had a negative trailing twelve-month return on equity of 59.29% and a negative net margin of 149.07%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Noxopharm investors own include AMC Entertainment (AMC), Dimerix (DXB), Align Technology (ALGN), Aurora Cannabis (ACB), Bandwidth (BAND), Alteryx (AYX) and Axcella Health (AXLA).

Company Calendar

Last Earnings
2/21/2019
Today
5/27/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:NOX
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.58 million
Net Margins
-149.07%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.40 million
Price / Cash Flow
15.42
Book Value
A$0.02 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$26.59 million
Optionable
Not Optionable
Beta
0.78
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (ASX:NOX) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners